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Background: In several countries, introduction of the pneumococcal conjugate vaccine 
(PCV) has led to a decline in antimicrobial-resistant pneumococcal disease but has also 
resulted in a concomitant increase in antimicrobial-resistant, non-vaccine serotypes of 
Streptococcus pneumoniae. We sought to determine the magnitude of penicillin and macro-
lide resistance among pneumococcal serotypes and the mechanisms of macrolide resistance 
in Ethiopia, 5 years after the introduction of PCV10 in the country.
Methods: Susceptibility to penicillin and erythromycin of 119 pneumococcal isolates collected 
from pediatric patients aged 0–15 years in Addis Ababa, Ethiopia, was tested using disc diffusion, 
and minimum inhibitory concentration (MIC) was also determined by Etest. Pneumococcal 
serotypes were determined by sequencing the cpsB gene and using Quellung reaction. 
Polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism analysis 
were used to detect and differentiate the macrolide resistance genes erm(B), mef(A), and mef(B).
Results: Among the 119 isolates, 2.5% (3/119) were resistant to penicillin, while 58% (69/119) 
were intermediate. Resistance to erythromycin was observed in 33.6% (40/119) of the isolates with 
the highest level of resistance among isolates from middle ear discharge, i.e., 53.3% (8/15). Half 
(19/40) of the erythromycin resistant isolates were serotype 19A and among serotype 19A isolates, 
the majority i.e., 54.3% (19/35) were resistant to erythromycin. The most common macrolide 
resistance determinant was mef(E) with a prevalence of 50% (20/40).
Conclusion: Five years after introduction of PCV10 in Ethiopia, we observed that the prevalence 
of penicillin-resistant S. pneumoniae was low. However, there was a high level of macrolide 
resistance which was mostly in serotype 19A, and the resistance was mainly mediated by efflux 
pumps. Introduction of PCV13 (which covers serotype 19A) would significantly improve coverage 
of the macrolide-resistant serotypes. Continued surveillance of pneumococcal serotype distribution 
and their antibiotic resistance pattern in Ethiopia is warranted.
Keywords: efflux pump, erythromycin, mef(E), PCV10, penicillin, serotype 19A, 
Streptococcus pneumoniae
Introduction
Streptococcus pneumoniae (pneumococcus) still remains the major cause of pneu-
monia, meningitis, bacteremia and otitis media among infants and young children, 
worldwide. A 2015 estimate indicates that globally, there were 294,000 deaths due 
to S. pneumoniae in children aged 1–59 months.1
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Penicillin non-susceptible pneumococci (PNSP) are on 
the priority list of antibiotic-resistant bacteria listed by the 
WHO for which research and development of new antibiotics 
are required.2 PNSP were first detected soon after the dis-
covery of penicillin3 and have since spread globally.4 
A recent meta-analysis of antimicrobial susceptibility pro-
files for pneumococcal pneumonia in sub-Saharan Africa 
indicated that the susceptibility to penicillin was 68.6%.5
Although the increasing prevalence of macrolide- 
resistant S. pneumoniae is raising concerns on the use of 
macrolides for treating pneumococcal diseases, they still 
remain an important group of antimicrobials.6 In the 
Ethiopian standard treatment guideline, macrolides are 
the first alternatives to β-lactams.7 Previous reports from 
Ethiopia indicate higher resistance to macrolides (23.9%) 
compared with other antibiotics (15.0% for penicillin and 
20.4% for amoxicillin), in nasopharyngeal pneumococcal 
isolates8 and a macrolide-resistance prevalence of 44.4% 
among isolates causing otitis media.9
Before the introduction of PCVs, the pneumococcal 
serotypes with highest level of resistance to penicillin 
and erythromycin were 6B, 6A, 9V, 14, 15A, 19F, 19A, 
and 23F, globally.10 After introduction of PCV7 in the 
vaccination schedule of various countries in the 2000s 
and higher valent PCV10 afterwards, there was 
a significant decline in antimicrobial-resistant pneumococ-
cal carriage and disease due to vaccine serotypes. This 
effect was however offset by the increasing resistance in 
non-vaccine serotypes, specifically serotype 19A.11
PCV10 was introduced in Ethiopia in October 2011 as 
a three dose primary series (3p+0) without any booster 
dose.12 The recent Ethiopian health and demographic sur-
vey indicated that 70.1% children aged < 3 years surveyed 
from the whole country and 93.1% of those from Addis 
Ababa received all three doses of PCV10.13 Most of the 
previous studies on penicillin resistance in S. pneumoniae 
in Ethiopia8,9 used the oxacillin disc diffusion test as 
a proxy for penicillin resistance and therefore lack accu-
racy. The CLSI criteria state that for isolates with oxacillin 
zones ≤ 19 mm, penicillin resistance should not be 
reported without performing a penicillin MIC test.14 In 
addition, there is a lack of data on the prevalence and 
distribution of PNSP serotypes in the post-PCV10 era.
In S. pneumoniae, macrolide resistance is mainly mediated 
by two mechanisms. The first one, target-site modification by 
erythromycin methylase (erm(B)) gene, usually confers high- 
level resistance and cross-resistance to lincosamides and 
streptogramin B drugs (MLSB phenotype). The second 
mechanism is mediated by mef class of genes that lead to 
active drug efflux and results in low- to mid-level resistance to 
macrolides (M phenotype). The mef gene has two variants, 
mef(A), originally found in Streptococcus pyogenes, and mef 
(E), which was first described in S. pneumoniae.15 The two 
mef genes have around 90% sequence homology and can be 
distinguished using specific primer sets. Due to the sequence 
similarity between the two genes, they were merged under 
mef(A) by Roberts and colleagues.16 In Ethiopia, in a study 
performed before the introduction of PCV10, the most com-
mon macrolide resistance determinant identified was mef(A/ 
E).17 There are however no data on the magnitude and mole-
cular mechanisms of macrolide resistance among different 
pneumococcal serotypes in the post-PCV10 era in Ethiopia. 
Therefore, the aim of this study was to determine the magni-
tude of penicillin and macrolide resistance among pneumo-
coccal serotypes and the mechanisms of macrolide resistance 
in Addis Ababa, Ethiopia, 5 years after the introduction of 
PCV10 in the country.
Materials and Methods
Study Sites and Source of Bacterial 
Isolates
The pneumococcal isolates were collected from 
September 2016–August 2017 from children aged 0–15 
years attending pediatric emergency departments at Black 
Lion and Yekatit 12 hospitals and pediatric outpatient 
departments in Girum hospital and Dr. Yared Pediatric 
Specialty Center, in Addis Ababa, Ethiopia. A total of 
119 S. pneumoniae isolates were collected, comprising 
89 from nasopharyngeal swabs of children with commu-
nity acquired pneumonia, 17 from nasopharyngeal swabs 
of children with non-respiratory illnesses, 5 from blood of 
children with pneumonia (n = 1) or sepsis (n = 4) and 15 
from middle ear swabs of children with acute otitis media. 
Serotypes of most of the pneumococcal isolates (except of 
the 17 isolates from nasopharyngeal swabs of children 
with non-respiratory illnesses) were previously determined 
and have been reported elsewhere.18–21
Antimicrobial Susceptibility Testing
Susceptibility to penicillin was initially determined using 
the Kirby-Bauer disk diffusion method.22 Oxacillin discs (1 
µg) were initially used and for isolates with zones of ≤ 
19 mm, the minimum inhibitory concentrations (MICs) 
were determined using Etest strips (bioMérieux, Marcy- 
l’Étoile, France). The results were classified as: susceptible 
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(≤ 0.06 μg/mL), intermediate (0.12–1 μg/mL), and resistant 
(≥ 2 μg/mL). To determine macrolide resistance, MICs were 
determined using Etest strips and results were classified as 
susceptible (MIC ≤ 0.25 µg/mL), intermediate (0.5 µg/mL), 
and resistant (≥ 1 µg/mL). Test results of both disc diffusion 
and MICs were interpreted according to the Clinical and 
Laboratory Standard Institute (CLSI) criteria.14 American 
Type Culture Collection (ATCC) strain S. pneumoniae 
ATCC 49619 was used for quality control.
DNA Extraction and Serotyping
DNA from S. pneumoniae isolates was extracted using 
alkaline lysis as previously described.23 Initial typing of 
pneumococcal isolates was done using PCRSeqTyping as 
previously described24 and consisted of amplification and 
sequencing of a 1061 bp region of the cpsB-gene. Sanger 
sequencing was performed at GATC Biotech (Constance, 
Germany) using 20 μL of the amplicons. cpsB sequences 
were then used to interrogate GenBank database (http:// 
www.ncbi.nlm.nih.gov/blast). BLAST bit score of > 99% 
sequence identity with reference sequences was used to 
assign serotypes. Because the correct serotype could not 
be assigned by PCRSeqTyping for some of the isolates, 
serotyping was performed on all isolates as well with the 
Quellung reaction25 using pool and group antisera, 
obtained from the Statens Serum Institut (Copenhagen, 
Denmark).
Detection of erm(B) and mef(A/E) Genes
PCR was used to detect macrolide resistance genes on all 
macrolide-resistant (MIC ≥ 1 µg/mL) isolates. 
Amplification of the ribosomal methylase (erm(B)) gene 
was performed using the primers: ermB-F, 5ʹ- 
GAAAAGGTACTAAACCAAATA-3ʹ and 5ʹ-AGTAACG 
GTACTTAAGTTTAC-3ʹ to generate a 639 bp PCR 
product.26 A PCR-restriction fragment length polymorph-
ism analysis was then performed in order to identify the 
presence of macrolide efflux genes mef(A/E) and discrimi-
nate between mef(A) and mef(E). The primer pair used was: 
MEF-F, 5ʹ-GCGTTTAAGATAAGCTGGCA-3ʹ and MEF- 
R, 5ʹ-CCTGCACCATTTGCTCCTAC-3ʹ, to generate 
a 1743-bp PCR product. PCR amplification consisted of 
35 cycles at 95°C, 54°C, and 72°C for 1 min each. The 
amplicons were then digested with the BamHI restriction 
enzyme.27
Results
Susceptibility to Penicillin and 
Erythromycin
The most prevalent serotypes in this study were serotypes 
19A (29.4%, 35/119), 16F (9.2%, 11/119), and non- 
typeables (6.7%, 8/119). PCV10 serotypes constituted 
11.7% (14/119) whereas PCV13-unique serotypes consti-
tuted 32.7% (39/119). Among the isolates, only 2.5% (3/ 
119) were resistant to penicillin, while 58% (69/119) had 
intermediate susceptibility and 39% (47/119) were suscep-
tible. The resistant isolates were serotype 19A (n = 2) and 
non typeable (n = 1). Among the isolates with intermediate 
susceptibility, most, 40.6% (28/69) were serotype 19A 
(Figure 1) and among serotype 19A isolates, the majority 
(80%, 28/35) showed intermediate susceptibility.
Resistance to erythromycin was observed in 33.6% 
(40/119) of the isolates overall. The highest level of ery-
thromycin resistance was seen among isolates from middle 
ear discharge, 53.3% (8/15), followed by nasopharyngeal 
isolates, 32.6% (29/89), and isolates from blood, 20% (1/ 
5) (Table 1). The resistance level to erythromycin by Etest 
MIC ranged between 3 and > 256 µg/mL, and most 
(65.8%) of the strains showed a high level of resistance 
(> 256 µg/mL). All the three isolates that were resistant to 
Figure 1 Pneumococcal serotypes from pediatric patients aged 0–15 years in Addis Ababa, Ethiopia and their susceptibility to penicillin.
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penicillin were also resistant to erythromycin. Overall, 
almost half (19/40) of the erythromycin-resistant isolates 
were serotype 19A and among serotype 19A isolates 
54.3% (19/35) were resistant (Figure 2). Among PCV10 
serotypes, 6B (2), 7F (1) and 19F (4) were all susceptible 
to erythromycin, whereas all of serotype 14 (1) and 23F 
(2) isolates were resistant to erythromycin.
Identification of Macrolide Resistance 
Determinants
The most common macrolide resistance determinant was 
mef (E), identified in 50% (20/40) of the strains while mef 
(A) was identified in only one strain (2.5%) (Table 1). 
Among those with mef (E), 55% (11/20) were serotype 
19A. Erm(B) was identified in three strains, two of which 
(serotype 1 and 19A) were positive for both erm(B) and 
mef(E) and both had a high level of resistance (MIC > 
256). Most of the strains which had mef(E), 65% (13/20) 
also showed high level of resistance (MIC > 256). In 40% 
(16/40) of the resistant erythromycin isolates, neither erm 
(B) nor mef(A/E) were detected.
Discussion
Because most antibiotic-resistant pneumococci are sero-
types included in PCV, the introduction of PCV has sig-
nificantly reduced the burden of antibiotic-resistant 
pneumococcal infections.28 In this study, performed 5 
years after introduction of PCV10 in Ethiopia, the preva-
lence of penicillin-non-susceptible (PNSP) isolates was 
only 2.5% whereas 58% were intermediate. In a study on 
Table 1 Source Sample, Serotypes and Genotypes of Macrolide-Resistant S. pneumoniae Isolates from Pediatric Patients Aged 0–15 
Years in Addis Ababa, Ethiopia
Serotype Total No. Antimicrobial 
Susceptibility
Source Sample Mechanism of Resistance
S R NP MES Blood erm(B) mef(A) mef(E)
1 2 1 1 1 1 1
11A 3 2 1 1
11D 1 1 1a
12B 1 1 1a
12F 3 2 1 1 1
14 1 1 1
15A 2 1 1 1 1
15B 3 2 1 1 1
16F 11 8 3 3 1
18A 2 1 1 1 1
20 2 1 1 1
19A 35 16 19 11 7 1 1 11
23A 2 1 1 1 1
23F 2 2 2a
35A 2 1 1 1 1
38 1 1 1 1
NT 8 5 3 2 1 2
Total No. 81 41 40 30 8 2 3 1 20
Note: aIdentified from children with non-respiratory infections. 
Abbreviations: S, susceptible; R, resistant; NP, nasopharyngeal swab; MES, middle ear swab.
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pneumococcal isolates from children with meningitis 
before the introduction of PCV10 in Ethiopia, 17% (8/ 
46) were intermediate and there were no PNSP isolates 
reported. The isolates with intermediate penicillin MIC 
levels were serotype 19F (n = 4), 14 (n = 3), and 7 (n = 
1).29 In Kenya, a country which introduced PCV10 around 
the same time as Ethiopia, a similar trend of penicillin 
susceptibility has been reported. Penicillin susceptibility 
among pneumococcal isolates from children aged < 5 
years indicated that prevalence of PNSP was low and 
remained unchanged in the pre-PCV10 period (2009), 
2.4% and post-PCV10 period (2013), 2.7% while most 
isolates were intermediate (77.6% in 2009 and 74.8% in 
2013).30 In most countries that reported a decline in anti-
microbial-resistant pneumococcal diseases, the prevalence 
of antimicrobial resistant vaccine-serotypes was high in 
the pre-PCV period.11 In South Africa for example, 4 
years after introduction of PCV7, incidence of invasive 
pneumococcal disease due to PNSP isolates among chil-
dren aged < 2 years of age declined by more than 80%.31 
In Brazil, PCV10 was introduced in 2010 and analysis of 
penicillin non-susceptibility among pneumococcal isolates 
recovered from carriage and invasive disease indicated 
a decline in the occurrence of PNSP among IPD isolates 
but an increase among carriage strains. The differences in 
impact of PCV on the prevalence of PNSP serotypes in 
different countries and regions indicates that antimicrobial 
resistance is multifactorial and might be influenced by the 
different antibiotic use policies and prevalence and nature 
of serotypes that emerged after introduction of PCV.11,32 
This also reinforces the need for continued long-term 
surveillance of the dynamic changes in antimicrobial resis-
tance among pneumococcal isolates due to PCV 
introduction.
In the current study, two out of the three PNSP isolates 
and most, 40.6% (28/69) of the penicillin intermediate iso-
lates were serotype 19A and among serotype 19A isolates 
the majority (80%, 28/35) were intermediate. In Brazil, after 
introduction of PCV10, serotype 19A was the most impor-
tant non-PCV10 serotype that emerged with increased pre-
valence in both carriage and disease.32 In addition, the rate 
of PNSP isolates among serotype 19A isolates increased 
significantly (11.4% to 64%, P < 0.001).33
Reports from many parts of the world indicate that 
macrolide-resistant S. pneumoniae are now more common 
than PNSP.34 In the current study, 33.6% of the pneumo-
coccal isolates were resistant to erythromycin out of which 
half were serotype 19A. Our findings were similar to 
a study on antimicrobial resistance among nasopharyngeal 
pneumococcal isolates from pediatric outpatients in 
Northern Ethiopia (33.2%) performed after the introduc-
tion of PCV10.35 In a study performed before the intro-
duction of PCV10 in Ethiopia on the distribution of 
nasopharyngeal pneumococcal serotypes before and after 
mass azithromycin treatment for trachoma in Northern 
Ethiopia, the prevalence of pneumococcal serotype 19A 
was quite low (2%).36 In the same study, the resistance 
level for azithromycin increased from 0% pre-treatment to 
50% post-treatment as it did for most other serotypes, 
indicating the impact of treatment on selection of antibio-
tic resistant strains. In Brazil, prevalence of erythromycin 
resistance among serotype 19A isolates from children aged 
< 5 years of age increased from 20.5% pre-PCV10 period 
to 85.7% in 6–7 years after PCV10 introduction and fac-
tors such as the pressure of vaccine and antimicrobial use 
and introduction and spread of multidrug resistant clones 
have been cited as possible reasons for this increase.33 In 
Ethiopia, although there is a lack of surveillance data on 
Figure 2 Pneumococcal serotypes from pediatric patients aged 0–15 years in Addis Ababa, Ethiopia and their susceptibility to erythromycin.
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antimicrobial resistance among different pneumococcal 
serotypes, the high prevalence of macrolide resistance 
especially among serotype 19A in this study may be due 
to the pressure of PCV10 and the use of antibiotics.
Results from a randomized double-blind trial that 
assessed the impact of PCV13 over PCV7 on reducing 
carriage of antibiotic-resistant pneumococci in Israel indi-
cated that PCV13 significantly reduced the acquisition of 
pneumococci non-susceptible to penicillin, erythromycin, 
and clindamycin, mainly seen in serotypes 19F, 6A, and 
19A.37 It is also hoped that the introduction of PCV13 in 
Ethiopia will help to reduce acquisition of antibiotic- 
resistant pneumococci, especially serotype 19A.
In the current study, the most common macrolide resistance 
mechanism was macrolide efflux, identified in 55% of the 
macrolide resistant isolates. The results were similar to the 
only previous study in Ethiopia that identified macrolide resis-
tance mechanisms.17 In that study, performed before the intro-
duction of PCV10 in Ethiopia, discrimination was not made 
between mef(A) and mef(E) genes. In the current study, macro-
lide efflux was the main macrolide resistance mechanism and 
mef(E) was the most common gene. Previous findings indicate 
that mef(E) is predominant in the United States, South Africa, 
and Asia while mef(A) is more common in Europe.38 Although 
macrolide resistance encoded by mef class of genes in 
S. pneumoniae is thought to confer low- to mid-level 
resistance,15 in our study, 65% of the strains with mef(E) had 
high level of resistance (MIC > 256 µg/mL). A recent study has 
indicated the ability of S. pneumoniae to generate high-level 
macrolide resistance by macrolide efflux and in the presence of 
macrolides, thus offering a fitness advantage to 
S. pneumoniae.39
In 40% (16/40) of the macrolide-resistant isolates, 
neither erm(B) nor mef(A/E) were detected. This indicates 
that other less common macrolide resistance mechanisms 
such as methyltransferase genes erm(A) and erm(C), the 
efflux pump gene mef(I), or mutations in 23S rRNA, L4, 
and L22 proteins might be responsible,40 which requires 
further investigation.
We acknowledge that our study had some limitations. 
First, the number of isolates is relatively small and more 
isolates would have been useful. Second, the focus of our 
study was on the most common macrolide resistance 
mechanisms and we did not test the presence of the less 
common macrolide-resistance mechanisms. Despite these 
limitations, however, to the best of our knowledge, this is 
the first report of the distribution of penicillin- and macro-
lide-resistant pneumococcal serotypes and the prevalence 
of macrolide-resistant pneumococcal genotypes in the 
post-PCV10 era in Ethiopia.
Conclusions
Findings from the study indicate that penicillin resistance 
among S. pneumoniae isolates, 5 years after the introduction 
of PCV10 in Ethiopia, is low, with most PNSP isolates being 
intermediately susceptible. Resistance to macrolides on the 
other hand was high and half of the isolates of the most 
prevalent serotype 19A were resistant to macrolides. Among 
macrolide-resistant isolates, the most common mechanism of 
resistance was macrolide efflux, with predominance of mef(E). 
Continued studies on the impact of antibiotic treatment and 
PCV on the prevalence and distribution of antibiotic-resistant 
pneumococcal serotypes in Ethiopia are warranted and intro-
duction of PCV13 would significantly enhance the coverage of 
the predominantly macrolide-resistant serotype 19A.
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